Microbiology: Low MIC Values

Consistently low MIC values – a potent addition to the treatment options for CAP^1,2

In Vitro Susceptibility: MIC Break Points Established by the CLSI for ZINFORO^®2,3,*

In vitro activity does not always correlate with clinical efficacy.
*Efficacy has been demonstrated in CAP clinical studies against the following pathogens that were susceptible to ceftaroline in vitro: S. pneumoniae, S. aureus (methicillin-susceptible strains only), E. coli, H. influenzae, H. parainfluenzae and K. pneumoniae. Efficacy has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to ceftaroline in vitro.^2
†The break point for susceptibility is based on a dosage regimen of ceftaroline 600 mg administered q12h.^3
‡Available clinical data cannot substantiate efficacy against PNSP. In vitro data indicate that the following atypical species are not susceptible to ceftaroline: Chlamydophila spp., Legionella spp., Mycoplasma spp., Proteus spp. and P. aeruginosa.^{2​​​​​}

CAP, community-acquired pneumonia; CLSI, Clinical and Laboratory Standards Institute; cSSTI, complicated skin and soft tissue infection; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; PNSP, penicillin-non–susceptible Streptococcus pneumoniae; q12h, every 12 hours.
​​​​​​​

References: